Unicycive Reports Q3 Loss as OLC Review Advances

Unicycive Therapeutics posted a third-quarter 2026 net loss of $7.0 million while its oxylanthanum carbonate application awaits an FDA decision.

Updated on Nov. 16, 2026 in Corporate Finance

Unicycive Reports Q3 Loss as OLC Review Advances

Unicycive Therapeutics, based in Mountain View, reported third-quarter 2026 results, with a net loss attributable to common stockholders of $7.0 million, or $0.25 per share. The company ended the period with $59 million in cash, cash equivalents, and marketable securities.

Why it matters

The results show a narrower per-share loss than a year earlier while the company prepares for a possible launch of its oxylanthanum carbonate product. The FDA's acceptance of a resubmitted application sets a clear regulatory timeline for the company's lead product.

Net loss attributable to common stockholders was $7.0 million, or $0.25 per share, versus $6.0 million, or $0.33 per share, a year earlier. Whether the FDA will approve the oxylanthanum carbonate application by its March 25, 2027 target date remains unresolved.

The players

Unicycive Therapeutics, Inc.

Unicycive Therapeutics is a biopharmaceutical company headquartered in Mountain View, California, developing oxylanthanum carbonate for treating patients with kidney disease.

U.S. Food and Drug Administration

The FDA is the federal agency that reviews and approves new drug applications in the United States and issued the Complete Response Letter and the application acceptance.

The details

The FDA issued a Complete Response Letter for oxylanthanum carbonate in June 2026, citing deficiencies previously identified at the original Drug Product vendor. The agency has since accepted the company's resubmitted new drug application and set a target action date of March 25, 2027.

Timeline

  1. June 2026: The FDA issued a Complete Response Letter for the oxylanthanum carbonate application.

  2. October 2026: The FDA accepted the resubmitted application.

  3. November 16, 2026: Unicycive reported third-quarter 2026 financial results.

  4. March 25, 2027: PDUFA target action date for the product.

Market Dynamics

Unicycive believes oxylanthanum carbonate meets the criteria for TDAPA upon FDA approval, a pathway that could shape the product's commercial protection. The company's cash runway is expected to extend beyond 2027, including anticipated increased expenses tied to a potential launch.

Investors tracking Unicycive can watch the March 25, 2027 FDA decision as the main near-term catalyst for the company's share value. The reported cash position and projected runway offer a baseline for assessing how long the company can fund operations before that decision.

The takeaway

Investors should weigh the company's cash runway against the regulatory timeline, since the March 2027 FDA decision will determine whether projected launch expenses are supported by approval. Tracking both the cash balance and the FDA calendar gives a clearer picture of the company's near-term position.

What happens next

The FDA's target action date for oxylanthanum carbonate is March 25, 2027.

Further reading

Explore more Corporate Finance coverage for context on how biotech companies fund drug development.

Source note: This article includes information reported by The Manila times.